PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII Russian patent published in 2020 - IPC A61K39/395 A61P7/04 

FIELD: medicine.

SUBSTANCE: group of inventions relates to a method of treating hemophilia A, comprising subcutaneous administration of a pharmaceutical composition which contains a bispecific antigen-binding molecule, recognizing coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X, where the antigen-binding molecule is administered subcutaneously in the initial dose and continued subcutaneously several times in doses for continuous administration, which are equal to the initial dose, wherein the interval between individual subcutaneous administrations is one week, wherein the antigen-binding molecule is a bispecific antibody in which the first and third polypeptides, as well as the second and fourth polypeptides are associated. Group of inventions also relates to use of said pharmaceutical composition for treating hemophilia A; application of a product containing a pharmaceutical composition, which contains a bispecific antigen-binding molecule, recognizing coagulation factor IX and/or activated blood coagulation factor IX and coagulation factor X and/or activated coagulation factor X, a container and instructions for use thereof, for treating hemophilia A.

EFFECT: group of inventions provides reduction of bleeding frequency year-on-year.

3 cl, 4 ex, 3 dwg, 3 tbl